This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Amgen Inc.. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: The Innovations of Aaron Avraham Nazarian
Introduction
Aaron Avraham Nazarian is an accomplished inventor based in Los Angeles, CA. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on cannabinoid receptor-1 (CB1) and its implications for treating various health conditions.
Latest Patents
Nazarian holds a patent for cannabinoid receptor-1 (CB1) monoclonal antibodies. This patent relates to CB1 receptor antigen-binding proteins, such as antibodies, and methods of using these antibodies. The CB1 receptor antibodies may include an antagonistic antibody to CB1 receptors, which can be utilized to treat health conditions like obesity and diabetes.
Career Highlights
Nazarian is currently associated with Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to explore innovative solutions in the medical field, particularly in the area of cannabinoid research.
Collaborations
Throughout his career, Nazarian has collaborated with notable colleagues, including Peter Coward and Steven A Moore, Jr. These partnerships have contributed to the advancement of his research and the development of new therapeutic approaches.
Conclusion
Aaron Avraham Nazarian's contributions to the field of biotechnology, particularly through his patent on CB1 monoclonal antibodies, highlight his innovative spirit and dedication to improving health outcomes. His work continues to pave the way for new treatments in medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile